Introduction
The Philadelphia (Ph) chromosome results from the reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11), which leads to a juxtaposition of 5′DNA sequences of the bcr gene on 22q11 with 3′DNA sequences of the abl oncogene from chromosome 9q34.1 in a head to tail fashion. 1, 2 Processing of hybrid transcript results either in an 8.5 kb chimeric messenger RNA (mRNA) that encodes a 210 kDa BCR-ABL protein or in a 7.5 kb mRNA encoding a 190 kDa fusion protein. 2, 3 For the p210 protein, exon b2 or b3 of the major breakpoint cluster region is joined to the abl exon 2 (b2-a2 or b3-a2 junction). 2 The 190 kDa protein results from a break within the minor breakpoint cluster region, splicing the first exon of the bcr gene to the abl gene (e1-a2 junction). 3 Rare fusion transcripts have been identified and are generated for example from a third breakpoint region in the bcr gene (-bcr) between exon e19 and e20 associated with a p230 protein (c3-a2 junction). 4 The p210 product is the hallmark of chronic myeloid leuke- mia (CML), 5 while p230 seems to be predominantly associated with chronic neutrophilic leukemia. 6 Studies on childhood and adult acute lymphoblastic leukemia (ALL) provided evidence that most patients carry p190 rather than p210 fusion products [7] [8] [9] [10] and established that the Ph chromosome is an important negative prognostic factor. 7, 8, 10, 11 In the context of risk-adapted therapy in adult ALL, rapid t(9;22) determination is of growing importance. Until recently, the diagnosis of a Ph chromosome relied on conventional chromosome banding analysis. 11 However, up to 20-30% of ALL patients lack adequate metaphases for karyotyping. 12, 13 Dual-color fluorescence in-situ hybridization (FISH) using DNA probes for BCR and ABL is a molecular-cytogenetic method that allows the detection of the Ph translocation on interphase nuclei. The disadvantage of false positives and false negatives of up to 5% each has hampered the diagnosis of a Ph translocation with this method in cases with low blast cell counts, 14 although recent improvements of the probes seem to overcome this problem. 15 Molecular techniques like polymerase chain reaction (RT-PCR) and Southern blot analysis can determine the individual breakpoint of DNA fusion products. In comparison to all other methods, RT-PCR has a high sensitivity and requires only small amounts of starting material. RT-PCR and cytogenetics revealed concordant results in about 90-100% of the cases, 12, 16 and RT-nested-PCR is the method of choice for the routine detection of the BCR-ABL recombination. Since only few t(9;22) translocations detectable by cytogenetic analysis are missed by RT-nested-PCR, 16 the major problem of the RT-nested-PCR approach is the possibility of a false positive result due to contamination.
One aim of this study was to evaluate prospectively the reliability of BCR-ABL RT-nested-PCR in the clinically relevant setting of central reference diagnostics in the context of the German multicenter trials for adult ALL (GMALL) by double testing of all positive and in part negative samples in two independent PCR assays. Patients were also analyzed by chromosome banding and/or FISH and these results compared to the PCR status.
Materials and methods

Patients and diagnosis
Pretreatment specimens were obtained from 2407 adults at initial diagnosis between January 1991 and April 2001. The diagnosis of ALL was confirmed by evaluating bone marrow and peripheral blood smears according to the French-American-British (FAB) criteria 17 and by immunophenotyping of bone marrow blast cells isolated by Ficoll-Hypaque density gradient centrifugation (Department of Hematology, Oncology and Transfusion Medicine, Berlin, Germany). Peripheral blood with substantial blast cell count was accepted for analysis, if the marrow was inaspirable or the sample too scanty. Details of the methods used for immunophenotyping and classification have been published elsewhere. 18, 19 Blineage differentiation of mostly TdT-positive blasts was diagnosed by expression of CD19 and additional B-markers (cytoplasmic CD22, CD79a, CD20), whereas a T-lineage differentiation was demonstrated by CD7, cytoplasmic CD3 and by additional markers (CD1, CD5, CD4, CD8, CD3) depending on the maturation status. In only nine cases could T-or B-lineage differentiation not be ascertained.
Molecular detection of the BCR-ABL fusion
One thousand four hundred and forty-two B-lineage ALL blasts and 11 samples of hybrid leukemia were selected for the prospective investigation of at least 5 × 10 6 cells. Cells were prepared from another fraction of the patients' bone marrow or peripheral blood sample on which ALL was diagnosed by immunophenotyping. BCR-ABL analysis was carried out in two institutions (Department of Hematology, Oncology, and Transfusion Medicine, Berlin, Germany and Institute of Human Genetics, Heidelberg, Germany). Total RNA was isolated from fresh or cryopreserved leukemia cells by standard methods. In the Heidelberg laboratory, c-DNA was prepared with random hexamers (Pharmacia), whereas in Berlin c-DNA synthesis used specific oligonucleotides (3′-ABL 9 ). For RTnested-PCR approaches, PCR protocols for detection of either ABL-ABL or BCR-ABL fusion products were applied as described in detail previously. 9 For RT-single-step-PCR, c-DNA synthesis was specifically primed by ABL-RT 5′-GAGTGTTTCTCCAGACTGTTGACTGGC-3′ and BCR-RT 5′-GCAGGTTGAGCATGCAGCTCTCCTTTGC-3′. RT-singlestep-PCR used in a multiplex-system the oligonucleotides BCR25i, 9 BRC-C, 20 CA3− 20 and C5e− 20 (40 cycles PCR) to amplify BCR-ABL and BCR-BCR.
From January 1991 to July 1999, all positive samples were tested by different RT-nested-PCR protocols in both laboratories. From July 1999 to April 2001, Berlin analyzed all samples by an initial RT-nested-PCR followed by a second RTsingle-step-PCR assay. Each control-PCR started with newly isolated RNA from a second fraction of the ALL cells. All recommended precautions were taken to avoid contaminations. A negative (sterile water) and a positive control were included in each amplification experiment. The following further precautions to ensure the accuracy of results were undertaken: (1) No cells, no RNA, and no amplified samples were allowed in the room where PCR mixtures were prepared. (2) No amplified samples were brought back into the room where RNA processing was performed. (3) The thermal cyclers were kept in a separate laboratory, away from the room where cell collection and RNA processing was performed.
Concordant results between two independent RT-PCR methods were classified as BCR-ABL-negative or -positive (p190 or m-BCR, p210 or M-BCR, p190/p210 or m-BCR/M-BCR). Divergent results were repeated at least two times and if consistently different amplicons were obtained, the PCR result was classified as ambiguous. Samples containing no amplifiable RNA were evaluated as insufficient.
Leukemia
Sensitivity of the RT-PCR methods
The sensitivity of the different RT-PCR methods was tested by dilution assays of K562 (b3a2), BV-173 (b2a2), and SD-1 cells (e1a2) in buffy coat cells. The dilution steps were prepared by a method described elsewhere 21 
Cytogenetic analysis and fluorescence in situ hybridization (FISH)
Cytogenetic analysis and FISH were performed in four laboratories on cell samples at initial diagnosis of ALL (Rieder, Marburg, Germany; Schoch, Mü nchen, Germany; Heinze, Ulm, Germany; Fonatsch, Lü beck, Germany). Five hundred and eighteen bone marrow samples were prepared prospectively for chromosome analysis and G-banded using a technique described elsewhere. 22 Chromosome abnormalities were identified and classified according to the International System for Human Cytogenetic Nomenclature. 23, 24 FISH was carried out on 55 samples prospectively and on 19 samples rectrospectively by commercially available directly labeled probes for BCR and ABL (VYSIS, Downer's Grove, IL, USA) as described.
14 The cut-off value for false positive nuclei was set at 6% (mean, plus 3 × standard deviation). 
14
Results
Sensitivity of the applied RT-nested-PCR and the RTsingle-step-PCR approaches
Concordance of first and second RT-PCR approaches
One thousand four hundred and fifty-three cell samples were analyzed by a first RT-nested-PCR for BCR-ABL fusion transcripts and 818 specimens were evaluated by a second RT-PCR approach that includes 642 initially BCR-ABL-positive ALL blasts (Table 1) . Parallel BCR-ABL RT-PCR analyses revealed a remarkably high number of samples that were positive in the first RT-nested-PCR and did not yield a BCR-ABL fusion in the second RT-PCR (n = 155). In 116 samples a third RT-PCR assay confirmed the results of the second RT-PCR indicating a false positive first RT-nested-PCR result caused by contamination. Thirty-seven samples remained ambiguous concerning the presence of a BCR-ABL fusion transcript. Two samples with a BCR-ABL transcript in the first RT-nested-PCR approach yielded another transcript in the second RT-PCR that was consistently obtained even in third RT-PCR assays. These two specimens were also classified as ambiguous.
Correlating the results of the control RT-PCR to the whole number of initially BCR-ABL-positive ALL cell samples studied, a false positive rate of 18% is evident. This rate of false positives was independent from the applied control RT-PCR method.
One hundred and seventy-six initially negative RT-nested- PCR results were controlled by a second independent RT-PCR approach (Table 1) . In 59 cases a RT-nested-PCR was performed as control-RT-PCR and in 117 samples a RT-single-step-PCR method was used. All together, two samples in the second RT-single-step-PCR approach yielded a BCR-ABL fusion signal that could be confirmed in further assays. These two samples were classified as BCR-ABL positive. The reasons for these false negative initial RT-nested-PCR results remained unclear and may be caused by mistakes of pipetting steps. Although each PCR approach included a control amplification step, low RNA quality is not completely ruled out since the ABL-ABL product of the initial RT-nested-PCR is rather short (106 bp). Table 1 gives a comprehensive overview on the overall incidence of BCR-ABL as determined by different RT-PCR approaches. Taking together the results of the different RT-PCR tests, 894 patients were diagnosed as BCR-ABL negative and 487 patients were BCR-ABL positive. Thirty-three patients were not evaluable because of insufficient cell samples. Thirty-nine patients could not be classified as either BCR-ABLnegative or BCR-ABL-positive even by several confirmatory RT-PCR procedures. These 39 samples were assigned as ambiguous.
Incidence of the BCR-ABL fusion as detected in two different RT-PCR approaches
Ambiguous RT-nested-PCR results
Thirty-nine blast cell samples remained ambiguous despite repetitive sampling by two independent RT-nested-PCR approaches. Thus, at least three different RT-PCR approaches were performed that did not generate a concordant, plausible result. Additional data by either cytogenetics (n = 15 patients) or FISH (n = 14) are available in 23 patients and details of these patients are given in Table 2 . In 18/23 samples with an ambiguous RT-PCR no Ph-translocation was detectable either by cytogenetics (n = 9), FISH (n = 5), or both methods (n = 4). Four specimens yielded a Ph-translocation either by FISH (n = 3) or both methods (n = 1). One additional sample with a normal karyotype revealed a co-localization of the ABL and BCR probe in the FISH analysis. Thus, in most but not all ambiguous RT-nested-PCR results a BCR-ABL-negative status may be present. For five patients a Ph-translocation could be confirmed by other methods.
Cytogenetic detection of the Ph-translocation and its comparison to the BCR-ABL status
Concurrent BCR-ABL and cytogenetic analyses were performed in 518 patients on cell samples (Table 3) . RT-nested-PCR failed to obtain an evaluable result in 42 patients (RT-PCR result either ambiguous or insufficient material; 8%), cytogenetics in 72 patients (14%), and both methods in 22 patients (4%). In the remaining 382 patients, 91% (n = 346) concordant results were obtained by cytogenetics and RT-nested-PCR. Positive RT-nested-PCR results were confirmed by karyotyping in 113 patients; 233 patients were BCR-ABL as well as t(9;22) negative. The results of 36 samples remained inconclusive comparing the results of RT-nested-PCR and cytogenetics. This includes six patients (two with a complex aberration) in which RT-nested-PCR analysis missed a BCR-ABL fusion protein. In one of these cases a variant t(9;22) was confirmed by in situ hybridization. In three of the remaining cases RT-nested-PCR was repeated retrospectively and identified one false negative initial RT-nested-PCR result. Cytogenetics did not confirm 30-positive RT-nested-PCR results. FISH was carried out in 16 of these samples and turned out to be positive in 14 patients tested. Thus, a consistently BCR-ABL-positive result in different RT-PCR assays is highly predictive for the presence of a t(9;22) even if the karyotype is normal. In this context, additional FISH analysis is of outstanding relevance.
Regarding the 72 cases without adequate cytogenetic data In each lane the number of patients is given. n.d., not done; Ph n.e., t(9;22) not evaluable; PCR n.e., insufficient material.
Leukemia but evaluable RT-nested-PCR result, FISH was done on 27 specimens. FISH confirmed in all BCR-ABL-positive samples a BCR-ABL fusion (n = 9). Seventeen of 18 BCR-ABL-negative samples also scored negative by FISH, but a positive FISH test was obtained in one case that has not undergone confirmatory RT-PCR.
Incidence of the BCR-ABL fusions as detected by controlled RT-nested-PCR in the various immunophenotypes
One thousand four hundred and fifty-three adults who received central immunophenotyping for diagnosis of ALL or hybrid leukemia between January 1992 and April 2001 (11 hybrid leukemia, 223 pro-B ALL, 937 c-ALL, 208 pre B-ALL, and 74 B-ALL) were investigated for the BCR-ABL recombination by controlled RT-nested-PCR. Ninety-eight percent of the samples (n = 1420) yielded an evaluable result, which includes the application of a second independent RT-PCR method in all cases with a BCR-ABL fusion transcript in the first RT-nested-PCR. Thirty-three percent (n = 487) of all the patients demon-strated consistently chimeric BCR-ABL fusion proteins including the p190-specific subtype in 70% (339/487), the p210 variant in 27% (134/487), and co-expression of the p190/p210 in only 3% (14/487) of the positive patients. As far as the specific amplification product has been documented (n = 126), p210-positive patients showed a b2a2 fusion in 84, a b3a2 transcript in 37, and a b2a2/b3a2 RNA in five patients each.
Regarding the different B-lineage immunophenotypes, the incidence of the BCR-ABL recombination differed markedly between the various subtypes. The BCR-ABL fusion proteins were detected in 43% c-ALL (400/937), and a frequency of 34% in pre-B-ALL (70/208). Only 5% of the pro-B ALL patients were BCR-ABL-positive (12/223), with a tendency for a higher frequency in blasts with myeloid coexpression (9%) as compared to leukemia cells lacking myeloid markers (3%). Interestingly, 5/11 hybrid leukemias transcribed BCR-ABL. In contrast, all B-ALL patients were BCR-ABL negative. There was no obvious difference in the distribution of the different BCR-ABL fusion products between the various immunophenotypes as shown in detail in Table 4 .
Discussion
Smaller cytogenetic and RT-PCR-based studies on adults with ALL 12,13,15,25,26 reported a widely varying 12% to 40% frequency of the Ph translocation. These varying incidences most likely reflect differences in success rates of chromosome testing in cytogenetic-based earlier trials or patient selection. One aim of this large prospective study was to determine the incidence of the BCR-ABL status in ALL patients. Thirty-three percent of our B-lineage ALL patients scored BCR-ABL positive leading to a calculated overall frequency of 20% for the whole adult ALL series studied. After negative results in 50 cases, an RT-nested-PCR analysis for BCR-ABL was omitted in T-lineage ALL, but we may assume that most T-lineage ALL cases were BCR-ABL negative. 7 We confirm, that the incidence of BCR-ABL-positive cases differs within the B-lineage immunophenotypes with the highest rate (43%) for c-ALL patients, followed by 34% for pre-B ALL, thus reflecting the known correlation between BCR-ABL-fusion and CD10-positive ALL given by other authors for smaller patients groups. 10 As expected, all B-ALL cases were BCR-ABL negative and only 5% of the pro-B ALL patients turned out to be BCR-ABL positive, underlining the minor role of the t(9;22) as compared to the t(4;11) in pro-B ALL patients. Since the reinvestigation for CD10 positivity Table 4 Incidence of BCR-ABL amplification products in the c-ALL, pre-B ALL, B-ALL, pro-B ALL and hybrid acute leukemia patients after confirmed RT-PCR approaches BCR-ABL status c-ALL pre-B ALL B-ALL pro-B ALL Hybrid AL Total n = 937 n = 208 n = 74 n = 223 n = 11 n = 1453 (2) 33 (2) Percentage in brackets.
with another antibody was not possible in the 12 BCR-ABLpositive pro-B ALL and one of these patients developed a c-ALL at relapse, the frequency of BCR-ABL in pro-B ALL may be even lower. To avoid such misinterpretation, a CD10 double test was applied for only weak CD10-positive cases (5-20% positive blasts) in our laboratory in the last years. As previously published for childhood 7 and adult ALL, 9, 10 our data underline the predominance of p190 (m-bcr) transcripts in comparison to p210 (M-bcr) variants in adult B-lineage ALL in contrast to some trials with less patient cohorts. 27, 28 Looking at the p210-positive group, b2a2 transcripts were more frequent than b3a2. Co-expression of p190/p210 was a rare event in our study (3%), but some authors reported a high rate of very low-level p190 in p210-positive leukemia by competitive RT-PCR. 29 Although the various BCR-ABL transcripts are known to have different oncogenic potential in vitro as well as in animal models, 30, 31 the biological differences between p190 and p210 remain enigmatic in ALL patients. There is an overlap of the disease spectra associated with the different BCR-ABL fusion proteins 32 also concerning expression of myeloid markers of ALL blasts, 33 and a high incidence of BCR-ABL products was recorded in the situation of hybrid leukemia in this study.
Earlier analysis on the incidence of this genetic lesion in ALL are mainly based on cytogenetic data, but prospective evaluation in the context of treatment stratification has not been performed. Illustrated by a failure rate of 18% in our study, shortcomings of karyotype analysis are frequently caused by the difficulty of growing lymphoid blasts, 12, 13 especially from peripheral blood. Moreover, the sensitivity of karyotyping is not comparable to RT-nested-PCR and some patients with an adequate number of metaphases may fail to demonstrate the translocation on cytogenetic analysis. In contrast, FISH has high sensitivity and is possible on interphase nuclei. However, also for FISH, the disadvantage of false positives and false negatives (up to 5% each) has to be considered. The application of probes that generate an extra signal substantially improved the frequeny of false positive results, 15 but due to this evaluation procedure, a higher rate of false negatives may not be ruled out. Furthermore, one-third of CML patients lack the extra signalling region of the Downer's Grove II probe and despite analysis in ALL blasts having not been performed, a similar frequency of deletions may be assumed. Although time-consuming, cytogenetics provides additional information on genomic alterations of the leukemic cell clone apart from the t(9;22). In contrast, molecular methods readily differentiate between p190 and p210. The clinical relevance of this discrimination has appeared to be of minor importance until now but might be important when new drugs, eg tyrosine kinase inhibitors, are applied.
RT-PCR is a rapid and cheap technique suitable for small sample amounts. Our data confirm that the results of RTnested-PCR and karyotype analysis agree in 90% of the cases. 12, 15 However, karyotyping was hampered by a higher failure rate. Only few t(9;22) translocations detectable by cytogenetic analysis were missed by RT-nested-PCR, although others reported up to 14% false negative PCR products. 12, 20 Our study finally showed ambiguous RT-PCR results in 3% of all cases, but initially had up to 24% false positives in the first RT-nested-PCR (153/640) despite scrupulous precautions being taken to minimize contaminations. These data are in accordance with a recent interlaboratory test for quality assurance of BCR-ABL RT-PCR, which detected false positive results in 30% of the 20 participating laboratories. 20 Thus, the possibility of a false positive result is a major concern in ALL patients due to the extraordinary sensitivity of BCR-ABL RT-PCR 33 and RT-PCR protocols are recommended to include a number of specific procedures to decrease PCR product carryover of amplified DNA. 34 In our experience, at least a second RT-nested-PCR or RT-single-step-PCR is warranted to guarantee reliable conclusions from the highly sensitive BCR-ABL RT-PCR approach. Like PCR diagnostics in virology, a double RT-PCR should be performed in every case. 35 In accordance with others, 20 multiplex RT-single-step-PCR is a suitable confirmatory RT-PCR strategy for ALL and less prone to contamination because of fewer pipetting steps. The performance of FISH is a successful, preferable alternative to confirmatory RT-PCR and is of growing importance shown by the widespread usage of FISH in molecular laboratories.
In the ALL patients reported, treatment stratification was performed individually in each study center on molecular genetic as well as cytogenetic and clinical risk features such as the age of disease onset and the white blood cell count. In the context of therapeutic application of tyrosine kinase inhibitors reliable determination of the Ph translocation is of growing importance. 36 For rapid clinical relevant information, RT-nested-PCR and FISH are the preferred methods. If RTnested-PCR is the only method applied, positive RT-PCR results require a confirmatory RT-PCR assay. Ambiguous RTnested-PCR results have to be clarified by FISH analysis. Phnegative cytogenetic analysis should be evaluated by molecular means. Since some samples could not be analyzed successfully by any applied method, careful sampling procedures prior to any treatment have to be performed to obtain results of utmost clinical relevance.
In conclusion, the Ph translocation is the major genetic event occurring in one-third of all B-lineage ALL patients with a different incidence in the various immunophenotypes. Our data confirm RT-nested-PCR as a rapid and sensitive method with a high success rate, but in the clinical context of therapeutic decisions in ALL confirmatory RT-PCR is highly recommended to improve specificity. From this point of view, cytogenetics and especially FISH analysis represent alternative approaches to obtain an unambiguous result on the BCR-ABL status.
